RANBAXY HONORED WITH NJBIA AWARD FOR EXCELLENCE IN NEW JERSEY BUSINESS EXPANSION

Princeton, NJ – October 11, 2011 -- Ranbaxy Inc., a research-based pharmaceutical company that manufactures generic product formulations, O-T-C and branded drug products, has been honored with the New Jersey Business Industry Association’s (NJBIA) Award for Excellence in Business Expansion and Economic Contribution to the State.

The NJBIA award acknowledges Ranbaxy’s commitment and contribution to the State, providing jobs for more than 700 New Jerseyans and with recent investments in its state-of-the-art manufacturing facilities in New Brunswick. NJBIA President Philip Kirschner will recognize Ranbaxy and other recipients at an awards dinner on October 18, 2011 in Edison, NJ.

Ranbaxy entered the U.S. market in 1994 with a sales office in Raleigh, North Carolina. It acquired Ohm Laboratories of North Brunswick, NJ, its first U.S. manufacturing facility in 1995 and subsequently relocated its North American headquarters to Princeton, NJ. Ohm Laboratories produces quality and affordable generic prescription product formulations, as well as O-T-C medications.

Acknowledging the honor, Venkat Krishnan, Senior Vice President and Regional Director, Americas, said, “In the past 24 months alone, Ranbaxy has invested more than $54.2 million in expanding its U.S. manufacturing and distribution capabilities. Currently, we have more than 700 employees, which is an increase of 36 percent from 2005. We are very proud of this recognition by the NJBIA, and we look forward to continuing growth as an active corporate citizen of the State of New Jersey.”

About Ranbaxy

Ranbaxy Inc., based in Princeton, New Jersey, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.